Supreme Court again limits where companies can be sued

Reuters

Published Jun 19, 2017 02:50PM ET

Updated Jun 19, 2017 03:01PM ET

Supreme Court again limits where companies can be sued

By Andrew Chung

WASHINGTON (Reuters) - The Supreme Court on Monday slapped limits on where injury lawsuits may be filed for the second time in three weeks, again siding with businesses that want to prevent plaintiffs from "shopping" for friendly courts for their cases.

In an 8-1 ruling, the justices overturned a lower court's decision that had allowed hundreds of out-of-state patients who took Bristol-Myers Squibb Co's (N:BMY) blood-thinning medication Plavix to sue the company in California.

State courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there, the justices ruled.

The Supreme Court on May 30 reached a similar conclusion in a separate case involving out-of-state injury claims against Texas-based BNSF Railway Co.

Businesses and plaintiffs are engaged in a battle over where lawsuits seeking financial compensation for injuries can be filed.

Companies typically can be sued in a state where they are headquartered or incorporated, as well as where they have important ties. Businesses want to limit the ability of plaintiffs to shop for courts in states with laws conducive to such injury lawsuits.

Plaintiffs contend that corporations are seeking to squeeze their access to compensation for injuries by denying them their day in state courts.

The underlying lawsuits filed in 2012 against Bristol-Myers and California-based drug distributor McKesson Corp (NYSE:MCK) involved 86 California residents and 575 non-Californians, alleging Plavix increased their risk of stroke, heart attack and internal bleeding.

Bristol-Myers argued it should not face claims in California by plaintiffs who do not live in the state. The company is incorporated in Delaware and headquartered in New York.

The California Supreme Court ruled in August 2016 that it could preside over the case because Bristol-Myers conducted a national marketing campaign and sold nearly $1 billion of the drug in the state.